Altesa BioSciences Announces Presentation at ERS 2025
Altesa BioSciences, a clinical-stage pharmaceutical company, is set to showcase groundbreaking data at the European Respiratory Society (ERS) International Congress 2025. This congress is a pivotal event in the respiratory medicine field, and Altesa's selection for a late-breaker presentation underlines the significance of its research.
Understanding Vapendavir and Its Impact
The late-breaker abstract, titled "Vapendavir for the Treatment of COPD Patients Challenged with Rhinovirus: A Phase 2a Placebo-Controlled Study," reveals compelling results from Altesa's recent trials. This research focused on vapendavir, an oral capsid inhibitor aimed at targeting rhinovirus, one of the main culprits behind exacerbations in Chronic Obstructive Pulmonary Disease (COPD).
Trial Results Indicating Promise
The clinical trial evaluated vapendavir's effectiveness in patients diagnosed with GOLD stage II COPD who were experimentally infected with rhinovirus A16. The findings suggest that vapendavir treatment led to notable improvements across various Patient-Reported Outcomes (PROs), particularly in addressing both upper and lower respiratory symptoms. Additionally, decreases in viral load and improvement in physiological biomarkers were observed, all validated by endpoints established by regulatory bodies like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Expert Insights on Vapendavir
Dr. Katharine Knobil, Altesa's Chief Medical Officer, emphasizes the revolutionary aspects of these results, addressing a significant gap in treatments for viral-induced exacerbations in COPD. Currently, no specific therapies exist for this urgent need, making vapendavir potentially transformative for millions affected by chronic lung diseases.
Presentation Highlights at ERS
The study, led by Professor Sebastian Johnston of the National Heart & Lung Institute at Imperial College London, is scheduled for presentation at the late-breaker session of ERS 2025. This key event will be held at 8 AM CEST on September 30, 2025. During this session, the audience will gain insights into the efficacy of vapendavir and its implications for respiratory medicine.
Upcoming Discussions and Symposium
Furthermore, the findings on vapendavir will feature prominently in an Industry Symposium at the ERS Congress 2025 on Sunday. This symposium will include discussions led by renowned pulmonary experts such as Professor Johnston and Professor Wisia Wedzicha, providing a platform for intense dialogue on the future of COPD treatments.
Dr. Brett Giroir, the Chief Executive Officer of Altesa, expressed gratitude for the enthusiasm shown by leading experts in this emerging treatment landscape. He highlighted the paradigm shift towards addressing the core causes of exacerbations rather than merely managing their consequences, a strategy that has yielded success in other viral infections like COVID-19.
Looking Forward: Future Trials
In response to the positive trial results, Altesa BioSciences plans to launch a Phase 2b multicenter, multinational randomized controlled trial targeting COPD patients experiencing natural rhinovirus infections. This ambitious study is anticipated to commence in early 2026, with results expected to be available by late 2027.
About Vapendavir
Vapendavir is an innovative oral treatment currently in advanced stages of clinical development by Altesa BioSciences. Preliminary findings indicate not only symptom alleviation but also reduced viral loads in patients affected by rhinovirus. If granted approval, vapendavir could significantly reduce the incidence of COPD exacerbations, enhancing the quality of life for patients while alleviating healthcare costs associated with exacerbation management.
About Altesa BioSciences
Altesa BioSciences is committed to advancing treatment options for individuals with chronic lung diseases, including COPD and asthma. The company is spearheaded by a team of distinguished professionals in respiratory medicine and infectious diseases, focusing on addressing the pivotal causes of disease exacerbation, namely viral respiratory infections. Alongside vapendavir, Altesa champions improved access to contemporary respiratory diagnostics and therapies in communities that are often underserved.
Media Contact: Mia Heck
Cellular: 210.284.0388
Frequently Asked Questions
What is Altesa BioSciences known for?
Altesa BioSciences specializes in developing treatments for chronic lung diseases, particularly focusing on COPD and asthma exacerbations caused by viral infections.
What is Vapendavir?
Vapendavir is an oral medication designed to target rhinovirus, aiming to reduce exacerbations and improve symptoms in patients with COPD.
When will the ERS 2025 presentation occur?
The presentation is scheduled for 8 AM CEST on September 30, 2025, during the late-breaker session at the ERS International Congress 2025.
What trials is Altesa planning?
Altesa BioSciences is preparing for a Phase 2b clinical trial to assess the effectiveness of vapendavir in COPD patients experiencing natural rhinovirus infections, starting in early 2026.
How does Vapendavir improve quality of life for COPD patients?
If approved, vapendavir could prevent up to 50% of COPD exacerbations, ultimately enhancing patients' quality of life and reducing healthcare burdens.
